Peter Gilbert

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. ncbi request reprint Endpoints in vaccine trials
    Michael G Hudgens
    Statistical Center for HIV Aids Research and Prevention, Program in Biostatistics, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Stat Methods Med Res 13:89-114. 2004
  2. ncbi request reprint Tests for comparing mark-specific hazards and cumulative incidence functions
    Peter B Gilbert
    Department of Biostatistics, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Lifetime Data Anal 10:5-28. 2004
  3. pmc On modeling HIV and T cells in vivo: assessing causal estimators in vaccine trials
    W David Wick
    Statistical Center for HIV and AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    PLoS Comput Biol 2:e64. 2006
  4. ncbi request reprint Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation
    Fusheng Li
    Statistical Center for HIV Aids Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Vaccine 24:6893-904. 2006
  5. ncbi request reprint Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study
    Ibou Thior
    Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Mass 02115, USA
    JAMA 296:794-805. 2006
  6. ncbi request reprint Simultaneous inferences on the contrast of two hazard functions with censored observations
    Peter B Gilbert
    Fred Hutchinson Cancer Research Center and Department of Biostatistics, University of Washington, Seattle, Washington 98109, USA
    Biometrics 58:773-80. 2002
  7. pmc Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials
    Peter B Gilbert
    Vaccine Infectious Disease Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington 98109, USA
    J Infect Dis 203:969-75. 2011
  8. ncbi request reprint Covariability of selected amino acid positions for HIV type 1 subtypes C and B
    Peter B Gilbert
    Department of Biostatistics, University of Washington, and Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    AIDS Res Hum Retroviruses 21:1016-30. 2005
  9. pmc Some design issues in phase 2B vs phase 3 prevention trials for testing efficacy of products or concepts
    Peter B Gilbert
    Vaccine Infectious Disease Institute, Fred Hutchinson Cancer Research Center and Department of Biostatistics, University of Washington, Seattle, WA 98109, USA
    Stat Med 29:1061-71. 2010
  10. pmc Semiparametric estimation of the average causal effect of treatment on an outcome measured after a postrandomization event, with missing outcome data
    Peter B Gilbert
    Department of Biostatistics, University of Washington, Seattle, WA 98105, USA
    Biostatistics 11:34-47. 2010

Research Grants

Detail Information

Publications50

  1. ncbi request reprint Endpoints in vaccine trials
    Michael G Hudgens
    Statistical Center for HIV Aids Research and Prevention, Program in Biostatistics, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Stat Methods Med Res 13:89-114. 2004
    ....
  2. ncbi request reprint Tests for comparing mark-specific hazards and cumulative incidence functions
    Peter B Gilbert
    Department of Biostatistics, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Lifetime Data Anal 10:5-28. 2004
    ..This assessment helps guide development of anti-HIV therapies that surmount the problem of drug resistance...
  3. pmc On modeling HIV and T cells in vivo: assessing causal estimators in vaccine trials
    W David Wick
    Statistical Center for HIV and AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    PLoS Comput Biol 2:e64. 2006
    ..In addition to uncovering a surprising immunological scenario, our results illustrate the utility of mechanistic modeling in biostatistics...
  4. ncbi request reprint Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation
    Fusheng Li
    Statistical Center for HIV Aids Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Vaccine 24:6893-904. 2006
    ..The usability of PTE peptide set was manifested by detection of Nef-specific CTL responses in HIV-1 subtype B infections...
  5. ncbi request reprint Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study
    Ibou Thior
    Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Mass 02115, USA
    JAMA 296:794-805. 2006
    ..Postnatal transmission of human immunodeficiency virus-1 (HIV) via breastfeeding reverses gains achieved by perinatal antiretroviral interventions...
  6. ncbi request reprint Simultaneous inferences on the contrast of two hazard functions with censored observations
    Peter B Gilbert
    Fred Hutchinson Cancer Research Center and Department of Biostatistics, University of Washington, Seattle, Washington 98109, USA
    Biometrics 58:773-80. 2002
    ..The simultaneous interval estimates are quite useful for identifying possible values of the contrast over time with a certain degree of confidence. The new proposals are illustrated with an example and a small simulation study...
  7. pmc Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials
    Peter B Gilbert
    Vaccine Infectious Disease Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington 98109, USA
    J Infect Dis 203:969-75. 2011
    ..Third, we evaluate RV144 for completeness of end point ascertainment and integrity of blinding, necessary tasks for establishing robustly interpretable results...
  8. ncbi request reprint Covariability of selected amino acid positions for HIV type 1 subtypes C and B
    Peter B Gilbert
    Department of Biostatistics, University of Washington, and Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    AIDS Res Hum Retroviruses 21:1016-30. 2005
    ..Information on covariability should be better exploited in assessments of HIV-1 diversity and how to surmount it with vaccine design...
  9. pmc Some design issues in phase 2B vs phase 3 prevention trials for testing efficacy of products or concepts
    Peter B Gilbert
    Vaccine Infectious Disease Institute, Fred Hutchinson Cancer Research Center and Department of Biostatistics, University of Washington, Seattle, WA 98109, USA
    Stat Med 29:1061-71. 2010
    ..Our objective is to help inform the decision-process for planning an initial efficacy trial design...
  10. pmc Semiparametric estimation of the average causal effect of treatment on an outcome measured after a postrandomization event, with missing outcome data
    Peter B Gilbert
    Department of Biostatistics, University of Washington, Seattle, WA 98105, USA
    Biostatistics 11:34-47. 2010
    ..The new method, which does not require a monotonicity assumption, is evaluated in a simulation study and is applied to data from the first HIV vaccine efficacy trial...
  11. pmc Evaluating a surrogate endpoint at three levels, with application to vaccine development
    Peter B Gilbert
    Fred Hutchinson Cancer Research Center and Department of Biostatistics, University of Washington, Seattle, WA 98109, USA
    Stat Med 27:4758-78. 2008
    ....
  12. pmc Efficient and robust method for comparing the immunogenicity of candidate vaccines in randomized clinical trials
    Peter B Gilbert
    Statistical Center for HIV Aids Research and Prevention, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave North, PO Box 19024, Seattle, WA 98109, USA
    Vaccine 27:396-401. 2009
    ..g., readouts from laboratory assays) of vaccine-induced immune responses, and (2) by implementing the proposed semiparametric efficient method in trials where baseline predictors are available...
  13. pmc Evaluating candidate principal surrogate endpoints
    Peter B Gilbert
    Department of Biostatistics, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington 98109, USA
    Biometrics 64:1146-54. 2008
    ..A CEP surface plot provides a way to compare the surrogate value of multiple biomarkers. The approach is illustrated by the problem of assessing an immune response to a vaccine as a surrogate endpoint for infection...
  14. ncbi request reprint The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy
    Peter B Gilbert
    Department of Biostatistics, University of Washington and Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109, USA
    Biostatistics 9:263-76. 2008
    ..The asymptotic properties of the procedures are established. In addition, the methods are studied in simulations and are applied to HIV genetic sequence data collected in the first HIV vaccine efficacy trial...
  15. ncbi request reprint Genome scanning tests for comparing amino acid sequences between groups
    Peter B Gilbert
    Fred Hutchinson Cancer Research Center and Department of Biostatistics, University of Washington, Seattle, WA 98109, USA
    Biometrics 64:198-207. 2008
    ..The methods are examined in simulations and are applied to two HIV examples. The methods for problem B address the general problem of comparing discrete frequency distributions between groups in a high-dimensional data setting...
  16. ncbi request reprint Failure time analysis of HIV vaccine effects on viral load and antiretroviral therapy initiation
    Peter B Gilbert
    Department of Biostatistics, University of Washington and Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109, USA
    Biostatistics 6:374-94. 2005
    ..The new method is evaluated in simulations and is applied to the vaccine trial data set...
  17. ncbi request reprint Two-sample tests for comparing intra-individual genetic sequence diversity between populations
    Peter B Gilbert
    Statistical Center for HIV Aids Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biometrics 61:106-17. 2005
    ..The new tests are evaluated theoretically and in a simulation study, and are applied to a dataset of 200 HIV sequences sampled from 21 children...
  18. ncbi request reprint Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal
    Peter B Gilbert
    Statistical Center for HIV Aids Research and Prevention, Fred Hutchinson Cancer Research Center and Department of Biostatistics, University of Washington, Seattle, WA 98105, U S A
    Stat Med 22:573-93. 2003
    ..40 and 3.86. Understanding the mechanisms by which HIV-1 infects more efficiently than HIV-2 may be useful in the development of HIV-1 vaccines. Additionally, the methodology developed here may be useful for analysing other data sets...
  19. ncbi request reprint What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials
    Peter B Gilbert
    Statistical Center for HIV Aids Research and Prevention, Fred Hutchinson Cancer Research Center, University of Washington, 1100 Fairview Avenue North, Seattle, WA 98109, USA
    J Infect Dis 188:179-93. 2003
    ..The assessment suggests that a vaccine demonstrating moderately durable effects to delay therapy and to ameliorate viremia merits consideration for licensure...
  20. ncbi request reprint Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials
    Peter B Gilbert
    Fred Hutchinson Cancer Research Center and Department of Biostatistics, University of Washington, Seattle, Washington 98109, USA
    Biometrics 59:531-41. 2003
    ..We show how the procedures can be used for a sensitivity analysis that quantifies how the causal effect of vaccination varies with the presumed magnitude of selection bias...
  21. pmc HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1
    Tomer Hertz
    Statistical Center for HIV Research and Prevention, Vaccine and Infectious Disease Division and the HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
    PLoS Pathog 9:e1003404. 2013
    ..Our findings have implications for vaccine design and suggest a framework by which different vaccine candidates can be compared in early phases of evaluation. ..
  22. pmc In pursuit of an HIV vaccine: designing efficacy trials in the context of partially effective nonvaccine prevention modalities
    Holly Janes
    1 Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
    AIDS Res Hum Retroviruses 29:1513-23. 2013
    ....
  23. ncbi request reprint Nonparametric estimation of the joint distribution of a survival time subject to interval censoring and a continuous mark variable
    Michael G Hudgens
    Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Biometrics 63:372-80. 2007
    ..Theoretical and empirical evidence are presented indicating the NPMLE and MIDMLE are inconsistent. Conversely, the CMLE is shown to be consistent in general and thus is preferred...
  24. pmc Assessing vaccine effects in repeated low-dose challenge experiments
    Michael G Hudgens
    Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Biometrics 65:1223-32. 2009
    ..Based on the principal stratification framework, we also address evaluation of potential immunological surrogate endpoints for infection...
  25. pmc Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study)
    Ann Duerr
    Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington 98109 1024, USA
    J Infect Dis 206:258-66. 2012
    ..97; P=1.0) over all follow-up time. Conclusions: The vaccine-associated risk seen in interim analysis was confirmed but waned with time from vaccination...
  26. ncbi request reprint HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine
    Peter B Gilbert
    Statistical Center for HIV Aids Research and Prevention, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, USA
    J Infect Dis 192:974-83. 2005
    ..The pre-ART viral load and CD4+ lymphocyte count trajectories were also comparable between the groups. Evidently, the vaccine did not affect HIV-1 disease progression...
  27. ncbi request reprint Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial
    Peter B Gilbert
    Statistical Center for HIV Aids Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    J Infect Dis 191:666-77. 2005
    ....
  28. ncbi request reprint Sensitivity analyses comparing outcomes only existing in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trials
    Bryan E Shepherd
    Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Biometrics 62:332-42. 2006
    ..We apply our methods to the world's first phase III HIV vaccine trial...
  29. doi request reprint Weighted likelihood method for grouped survival data in case-cohort studies with application to HIV vaccine trials
    Zhiguo Li
    Department of Biostatistics, University of Michigan, Ann Arbor, Michigan 48109, USA
    Biometrics 64:1247-55. 2008
    ..We apply the method to the HIV vaccine trial data, showing that higher antibody levels are associated with a lower hazard of HIV infection...
  30. pmc HIV-1 vaccines and adaptive trial designs
    Lawrence Corey
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Sci Transl Med 3:79ps13. 2011
    ....
  31. ncbi request reprint A framework for assessing immunological correlates of protection in vaccine trials
    Li Qin
    Statistical Center for HIV Aids Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Infect Dis 196:1304-12. 2007
    ..Other real and simulated examples are also discussed...
  32. pmc Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments
    Michael G Hudgens
    Department of Biostatistics, School of Public Health, University of North Carolina, Chapel Hill, NC 27599, USA
    J Infect Dis 200:609-13. 2009
    ..Power generally increases with the maximum number of allowable challenges per animal, the per-exposure risk of infection in control animals, and the proportion of animals susceptible to infection...
  33. pmc Predicting the impact of blocking human immunodeficiency virus type 1 Nef in vivo
    W David Wick
    Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, M2 C200, 1100 Fairview Ave N, Seattle, Washington 98109 1024, USA
    J Virol 83:2349-56. 2009
    ..We conclude that inhibiting Nef could make a substantial reduction in disease burden, lengthening the time before the necessity of undertaking combination therapy with other antiretroviral drugs...
  34. ncbi request reprint Statistical evaluation of HIV vaccines in early clinical trials
    Zoe Moodie
    Statistical Center for HIV Aids Research and Prevention, Fred Hutchinson Cancer Reasearch Center, 1100 Fairview Ave N, LE 400, PO Box 19024, Seattle, WA 98109 1024, USA
    Contemp Clin Trials 27:147-60. 2006
    ..The goal of these early trials is to narrow the number of candidate vaccines to the most promising candidates worthy of further study in efficacy trials...
  35. ncbi request reprint HIV-1 CTL-based vaccine immunogen selection: antigen diversity and cellular response features
    Fusheng Li
    Statistical Center for HIV Aids Research and Prevention, 1100 Fairview Avenue N, Seattle, WA 98109, USA
    Curr HIV Res 5:97-107. 2007
    ..Based on these analyses, several approaches are proposed to enhance the breadth of vaccine responses and, hence, the potential protective efficacy...
  36. ncbi request reprint Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160
    Deborah Lee
    Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    J Infect Dis 190:903-7. 2004
    ..4, P =.1, and P =.7, respectively). Persons who acquire HIV-1 infection while enrolled in HIV-1 vaccine trials can be successfully followed after infection, to determine whether vaccines alter the course of HIV-1 infection...
  37. ncbi request reprint Identification of cross-neutralization determinants by GAP analysis: a mutational behavior approach
    Fusheng Li
    Statistical Center for HIV Aids Research and Prevention, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109, USA
    Curr HIV Res 5:87-96. 2007
    ..Correlated mutation analysis and structure mapping further refine the cross-neutralization determinants. The usability of this approach is confirmed by analysis of an Influenza H3N2 cross-reactive dataset...
  38. pmc Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine
    Peter Gilbert
    Vaccine Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    J Infect Dis 202:595-605. 2010
    ..Here we assessed the magnitude and breadth of neutralizing antibody responses in Vax004...
  39. pmc Statistical identifiability and the surrogate endpoint problem, with application to vaccine trials
    Julian Wolfson
    Department of Biostatistics, University of Washington, Seattle, Washington 98195 7232, USA
    Biometrics 66:1153-61. 2010
    ....
  40. ncbi request reprint Accuracy and precision of estimating intervention efficacy when the timing of observed events differ by treatment arm
    Amalia S Meier
    University of Washington, USA
    Contemp Clin Trials 26:598-610. 2005
    ..Efforts to re-capture subjects at the end of study for failure assessment are helpful in some contexts, and may be considered in study planning...
  41. pmc nCal: an R package for non-linear calibration
    Youyi Fong
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Bioinformatics 29:2653-4. 2013
    ..nCal supports a simple graphical user interface that can be used by laboratory scientists, and contains functionality for importing data from the multiplex bead array assay instrumentation...
  42. doi request reprint Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop
    Christopher S Coffey
    Department of Biostatistics, University of Iowa, Iowa City, USA
    Clin Trials 9:671-80. 2012
    ..These recommendations have since been presented, discussed, and vetted in a number of venues including the University of Pennsylvania Conference on Statistical Issues in Clinical Trials and the Society for Clinical Trials annual meeting...
  43. pmc MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load
    Holly Janes
    Division of Vaccines and Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
    PLoS ONE 7:e43396. 2012
    ..We linked the viral sequence data with immune response and acute viral load data to explore mechanisms for and consequences of the observed sieve effect...
  44. ncbi request reprint Interactive association of proviral load and IFN-gamma-secreting T cell responses in HIV-1C infection
    Vladimir A Novitsky
    Department of Immunology and Infectious Diseases, Harvard School of Public Health, FXB 402, 651 Huntington Avenue, Boston, MA 02115, USA
    Virology 349:142-55. 2006
    ....
  45. ncbi request reprint Flexible weighted log-rank tests optimal for detecting early and/or late survival differences
    Lang Wu
    Department of Statistics, University of British Columbia, Vancouver, British Columbia V6T 1Z2, Canada
    Biometrics 58:997-1004. 2002
    ..When the main interest is in detecting early and/or late survival differences, these tests may be preferable to the other versatile and weighted log-rank tests that have been studied...
  46. ncbi request reprint Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana
    Roger L Shapiro
    Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    AIDS 20:1281-8. 2006
    ..Single-dose nevirapine given to women and infants reduces mother-to-child HIV transmission, but nevirapine resistance develops in a large percentage of women...
  47. ncbi request reprint A comparison of eight methods for the dual-endpoint evaluation of efficacy in a proof-of-concept HIV vaccine trial
    Devan V Mehrotra
    Merck Research Laboratories, UN A102, 785 Jolly Road, Blue Bell, Pennsylvania 19422, USA
    Biometrics 62:893-900. 2006
    ..The adjustment is derived using a selection bias model based on the principal stratification framework of causal inference...
  48. ncbi request reprint Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate
    Donald N Forthal
    Division of Infectious Diseases, Department of Medicine, University of California, Irvine, CA 92697, USA
    J Immunol 178:6596-603. 2007
    ..However, such activity requires the presence of FcR-bearing effector cells. Our results provide further evidence that ADCVI may play a role in preventing HIV infection...
  49. ncbi request reprint Prognostic significance of DCC and p27Kip1 in colorectal cancer
    James T Wu
    Department of Pathology, University of Illinois, Chicago, Medical Center, Chicago, IL, USA
    Appl Immunohistochem Mol Morphol 13:45-54. 2005
    ..87; 95% confidence interval, 0.58-1.29; P=0.49). The present study demonstrated that the expression of neither DCC nor p27Kip1 was predictive in poor survival outcome in patients with stage II or III colorectal cancer...
  50. ncbi request reprint HIV-1 subtype C in vitro growth and coreceptor utilization
    Thumbi Ndung'u
    Botswana Harvard School of Public Health AIDS Initiative Partnership for HIV Research and Education, Private Bag BO320, Bontleng, Gaborone, Botswana, Africa
    Virology 347:247-60. 2006
    ..Usage of other coreceptors was rare and apparently insignificant. These results enhance our understanding of HIV-1C biology, with implications for designing and testing therapeutic and prophylactic agents...

Research Grants7

  1. Statistical Methods in HIV Vaccine Efficacy Trials
    Peter Gilbert; Fiscal Year: 2009
    ..By improving the design and analysis of efficacy and NHP trials for addressing these areas, the project will benefit public health. ..
  2. Statistical Methods in HIV Vaccine Efficacy Trials
    Peter Gilbert; Fiscal Year: 2003
    ..g., immune responses). The fourth aim is to develop accurate simultaneous confidence interval procedures for assessing time-varying effects of vaccination to prevent infection or post-infection outcomes. ..
  3. Statistical Methods in HIV Vaccine Efficacy Trials
    Peter Gilbert; Fiscal Year: 2004
    ..g., immune responses). The fourth aim is to develop accurate simultaneous confidence interval procedures for assessing time-varying effects of vaccination to prevent infection or post-infection outcomes. ..
  4. Statistical Methods in HIV Vaccine Efficacy Trials
    Peter Gilbert; Fiscal Year: 2005
    ..g., immune responses). The fourth aim is to develop accurate simultaneous confidence interval procedures for assessing time-varying effects of vaccination to prevent infection or post-infection outcomes. ..
  5. Statistical Methods in HIV Vaccine Efficacy Trials
    Peter Gilbert; Fiscal Year: 2006
    ..By improving the design and analysis of efficacy and NHP trials for addressing these areas, the project will benefit public health. ..
  6. Statistical Methods in HIV Vaccine Efficacy Trials
    Peter Gilbert; Fiscal Year: 2007
    ..By improving the design and analysis of efficacy and NHP trials for addressing these areas, the project will benefit public health. ..